EUVIMEDEUVIMED entdecken
Studienprotokoll

Cannabidiol as a Treatment for Neurobiological, Behavioral, and Psychological Symptoms in Early-Stage Dementia: A Double-Blind, Placebo-Controlled Clinical Trial Protocol

Jessica G Bartschi iD, Lisa-Marie Greenwood, Amy Montgomery, Lon Dortants, Katrina Weston-Green, Xu-Feng Huang iD, Nagesh Pai, Jan Potter, Mark M Schira, Rodney Croft, Nadia Solowij

Cannabis & Cannabinoid Research · 01.04.2023 · 8 (2) · 348-359

DOI: 10.1089/can.2021.0209 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 30.03.2023. Verfasst von Jessica G Bartschi und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychology, Faculty of the Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, Australia. Hauptthemen laut MEDLINE: Cannabidiol, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

The slowing of disease progression in dementia in the early stages of diagnosis is paramount to improving the quality of life for those diagnosed and their support networks. Accumulating evidence suggests that CBD, a constituent of Cannabis sativa , is associated with neuroprotective, neuroendocrine, and psychotherapeutic effects, suggesting that it may be beneficial to dementia treatment. However, no published human study to date has examined this possibility. This trial aims to determine whether daily treatment with CBD over a 12-week period is associated with improved neurobiological, behavioral, and psychological outcomes in individuals living with early-stage dementia.

Methods

Sixty participants with early-stage dementia will be recruited for a randomized, double-blind, placebo-controlled clinical trial. Participants will be randomized into either 99.9% pure CBD or placebo treatment conditions and administered two capsules per day for 12 weeks. Participants will commence a 200 mg/day dose for 2 weeks before escalating to 300 mg/day for the remaining 10 weeks. Neuroimaging and blood-based neuroendocrine profiles will be assessed at baseline and post-treatment. Psychological and behavioral symptoms will be assessed at baseline, 6 weeks, and post-treatment. Monitoring of health and side-effects will be conducted through weekly home visits.

Discussion

This study is among the first to investigate the effects of isolated CBD in improving neuroanatomical and neuroendocrine changes, alongside psychological symptoms, during the early stages of dementia diagnosis. The outcomes of this trial have the capacity to inform a potential novel and accessible treatment approach for individuals living with early-stage dementia, and in turn, improve quality of life, prognoses, and treatment outcomes. Trial Registration: This trial has been registered with the Therapeutic Goods Administration (CT-2020-CTN-03849-1v2) and the Australian and New Zealand Clinical Trials Registry (ACTRN12621001364864).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDementiaHumansQuality of LifeAustraliaTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

behavioral and psychological symptoms of dementia (BPSD)braincannabidiolclinical trialdementiahormonesneurodegeneration

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • School of Psychology, Faculty of the Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, Australia.
  • Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia.
  • Australian Center for Cannabinoid Clinical and Research Excellence (ACRE), New Lambton Heights, Australia.
  • Research School of Psychology, The Australian National University, Canberra, Australia.
  • School of Nursing, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia.
  • School of Medicine and Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia.

ORCID-Profile: Jessica G Bartschi, Xu-Feng Huang

Zitieren

APA

Bartschi, J. G., Greenwood, L. M., Montgomery, A., Dortants, L., Weston-Green, K., Huang, X. F., Pai, N., Potter, J., Schira, M. M., Croft, R., & Solowij, N. (2023). Cannabidiol as a Treatment for Neurobiological, Behavioral, and Psychological Symptoms in Early-Stage Dementia: A Double-Blind, Placebo-Controlled Clinical Trial Protocol. Cannabis & Cannabinoid Research, 8(2), 348-359. https://doi.org/10.1089/can.2021.0209

Vancouver

Bartschi JG, Greenwood LM, Montgomery A, Dortants L, Weston-Green K, Huang XF, et al. Cannabidiol as a Treatment for Neurobiological, Behavioral, and Psychological Symptoms in Early-Stage Dementia: A Double-Blind, Placebo-Controlled Clinical Trial Protocol. Cannabis & Cannabinoid Research. 2023;8(2):348-359. doi:10.1089/can.2021.0209

BibTeX
@article{Bartschi2023,
  author = {Bartschi, Jessica G and Greenwood, Lisa-Marie and Montgomery, Amy and Dortants, Lon and Weston-Green, Katrina and Huang, Xu-Feng and Pai, Nagesh and Potter, Jan and Schira, Mark M and Croft, Rodney and Solowij, Nadia},
  title = {Cannabidiol as a Treatment for Neurobiological, Behavioral, and Psychological Symptoms in Early-Stage Dementia: A Double-Blind, Placebo-Controlled Clinical Trial Protocol},
  journal = {Cannabis & Cannabinoid Research},
  year = {2023},
  volume = {8},
  number = {2},
  pages = {348--359},
  doi = {10.1089/can.2021.0209}
}
Kostenlos starten →